

DAFTAR PUSTAKA

- Aalders, K.C., Tryfonidis, K., Senkus, E., and Cardoso, F. 2017. Anti-Angiogenic Treatment in Breast Cancer: Facts, Successes, Failures, and Future Perspective. *Cancer Treatment Reviews*. 53: 98-110.
- Agarwal, V., Bell, G.W., Nam, J-W., *et al.* 2015. Predicting Effective MicroRNA Target Sites in Mammalian mRNAs. *eLife*. 4: 1-38.
- Ahmadinejad, F., Mowla, S., Honardoost, M., *et al.* 2017. Lower Expression of miR-218 in Human Breast Cancer is Associated with Lymph Node Metastases, Higher Grades, and Poorer Prognosis. *Tumour Biology*. 39(8): 1-12.
- Akhtar, M.M., Micolucci, L., Islam, M.S., *et al.* 2016. Bioinformatic Tools for MicroRNA Dissection. *Nucleic Acids Res.* 44(1): 24-44.
- Ali, S., Rasool, M., Chaoudhry, H., *et al.* 2016. Molecular Mechanism and Mode of Tamoxifen Resistance in Breast Cancer. *Bioinformation*. 12(3): 135-139.
- Allison, K.H. 2012. Molecular Pathology of Breast Cancer. *Am. J. Clin. Pathol.* 138: 770-780.
- Amandito, R., Viryawan, C., Santoso F., *et al.* 2013. The Characteristocs of Breast Cancer Patients in “Dharmais” Hospital National Cancer Center Jakarta Based on Occupational and Enviromental Status. *Indonesia Journal of Cancer*. 7(2): 53-59.
- American Cancer Society. 2017. Breast Cancer Facts & Figures 2017-2018. *American Cancer Society, Inc.* 1-44.
- Asghari, F., Haghnavaaz, N., Baradaran, B., *et al.* 2016. Tumor Suppresor MicroRNAs: Targeted Molecules and Signaling Pathways in Breast Cancer. *Biomedicine and Pharmacotherapy*. 81: 305-317.
- Aure, M.R., Vitelli, V., Jernström, S., *et al.* 2017. Integrative Clustering Reveals a Novel Split in The Luminal A Subtype of Breast Cancer. *Breast Cancer Research*. 19(44): 1-18.
- Bahrani, A., Hasanzadeh, M., Hassanian, S.M., *et al.* 2017. The Potential Value of The PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therpy. *J. Cell. Biochem.* 119(1): 213-222.
- Bartel, D.P. 2004. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. *Cel.* 116(2): 281-297.
- Bergers, G. and Benjamin, L E. 2002. Tumorigenesis and The Angiogenic Switch. *Nature Reviews*. 3: 401-410.
- Bertoli, G., Cava, C., and Castiglioni, I. 2015. MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. *Theranostics*. 5(10): 1122-1143.
- Bhan, A. and Mandal, S.S. 2015. LncRNA HOTAIR: A Master Regulator of Chromatin Dynamics and Cancer. *Biochims. Biophys. Acta*. 1856(1): 151-164.
- Blenkiron, C., Goldstein, L.D., Thorne, N.P., *et al.* 2007. MicroRNA Expression Profiling of Human Breast Cancer Identifies New Markers of Tumor Subtype. *Genome Biol.* 8(10): 1-16.
- Block, I., Burton, M., Sorensen, K., *et al.* 2018. Association of miR-548c-5p, miR-7-5p, miR-210-3p, miR-218-3p with Reccurence in Systematically Untreated

- Breast Cancer. *Oncotarget*. 9(10): 9030-9042.
- Bombonati, A. and Sgroi, D.C. 2011. The Molecular Pathology of Breast Cancer Progression. *J. Pathol.* 223(2): 307-317.
- Bujor, I.S., Cioca, A., Ceausu, R.A., *et al.* 2018. Evalution of Vascular Proliferation in Molecular Subtypes of Breast Cancer. *In Vivo*. 32(1): 79-83.
- Bunch, H. 2017. Gene Regulation of Mammalian Long Non-Coding RNA. *Mol. Genet. Genomics*. 1-15.
- Burrell, K. and Zadeh, G. 2012. *Tumor Angiogenesis*. InTech. Croatia. pp: 276-296.
- Buysschaert, I., Schmidt, T., Roncal, C., *et al.* 2008. Genetics, Epigenetics and Pharmaco-(epi)genomics in Angiogenesis. *J. Cell. Mol. Med.* 12(6B): 2533-2551.
- Braza-Boils, A., Mari-Alexandre, Gilabert, J., *et al.* 2014. MicroRNA Expression Profile in Endometriosis: Its Relation to Angiogenesis and Fibrinolytic Factors. *Human Reproduction*. 29(5): 978-988.
- Cai, Y., Yu, S., Hu, S., *et al.* 2009. A Brief Review on the Mechanisms of miRNA Regulation. *Genomics Proteomics Bioinformatics*. 7(4): 147-154.
- Cammaerts, S., Strazisar, M., Rijk, P.D., *et al.* 2015. Genetic Variants in MicroRNA Genes: Impact on MicroRNA Expression, Function, and Disease. *Frontier in Genetics*. 6(186): 1-12.
- Camps, C., Saini, H.K., Choundhry, H., *et al.* 2014. Integrated Analysis of MicroRNA and mRNA Expression and Association with HIF Binding Reveals The Complexity of MicroRNA Expression Regulation Under Hypoxia. *Molecular Cancer*. 13(28): 1-21.
- Cao, J. 2014. The Functional Role of Long Non-Coding RNAs and Epigenetics. *Biological Procedures Online*. 11(16): 1-13.
- Cao, Y. 2016. Future Options of Anti-Angiogenic Cancer Therapy. *Chin J Cancer*. 35(21): 1-9.
- Caporali, A. and Emanuelli, C. 2011. MicroRNA Regulation in Angiogenesis. *Elsevier*. 55: 79-86.
- Carmeliet, P. 2003. Angiogenesis in Health and Disease. *Nature Medicine*. 9(6): 653-660.
- Carmeliet, P. and Jain, R.K. 2011. Molecular Mechanism and Clinical Applications of Angiogenesis. *Nature*. 473(7347): 298-307.
- Cerrato, F. and Labow, B.I. 2013. Diagnosis and Management of Fibroadenomas in the Adolescent Breast. *Seminars in Plastic Surgery*. 27: 23-25.
- Chang, J.T-H., Wang, F., Chapin, W., *et al.* 2016. Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas. *pLos One*. 11(2): 1-13.
- Cheetam, S.W., Gruhl, F., Mattick, J. S., *et al.* 2013. Long Noncoding RNAs and The Genetics of Cancer. *British Journal of Cancer*. 108: 2419-2425.
- Chen, D., Dang, B.L., Huang, J.Z., *et al.* 2015. miR-373 Drives the Epithelial-to-Mesenchymal Transition and Metastasis via the miR-373-TXNIP-HIF1 α -TWIST Signaling Axis in Breast Cancer. *Oncotarget*. 6(32): 32701-32712.
- Ciriello, G., Sinha, R., Hoadley, K.A., *et al.* 2013. The Molecular Diversity of Luminal A Breast Tumors. *Breast Cancer Res Treat.* 141: 409-420.
- Coxon, A., Bush, T., Saffran, D., *et al.* 2009. Broad Antitumor Activity in Breast

- Cancer Xenografts by Motesanib, A Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-derived Growth Factor, and Kit Receptors. *15*(1): 110-118.
- Cuk, K., Zucknick, M., Heil, J., *et al.* 2013. Circulating MicroRNAs in Plasma as Early Detection Markers for Breast Cancer. *International Journal of Cancer*. *132*(7): 1602-1612.
- Dai, X., Xiang, L., Li, T., *et al.* 2016. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes. *Journal of Cancer*. *7*: 1281-1294.
- Dang, L.T.H., Lawson, N.D., and Fish, J.E. 2013. MicroRNA Control of Vascular Endothelial Growth Factor Signaling Output During Vascular Development. *Journal of The American Heart Association*. 192-200.
- Das, K., Chan, X.B., Epstein, D., *et al.* 2016. NanoString Expression Profiling Identifies Candidate Biomarkers of RAD001 Response in Metastatic Gastric Cancer. *ESMO Open*. *1*: 1-11.
- Davis, G. E., Stratman, A. N., Sacharidou, A., *et al.* 2011. Molecular Basis for Endothelial Lumen Formation and Tubulogenesis During Vasculogenesis and Angiogenic Sprouting. *Int. Rev. Cell. Mol. Biol.* *288*: 101-165.
- De Abreu, F.B., Wells, W.A., and Tsongalis, G.J. 2013. The Emerging Role of The Molecular Diagnostics Laboratory in Breast Cancer Personalized Medicine. *The American Journal of Pathology*. *183*(4): 1075-1083.
- de Rinaldis, E., Gazinska, P., Mera, A., *et al.* 2013. Integrated Genomic Analysis of Triple-Negative Breast Cancers Reveals Novel MicroRNAs Associated with Clinical and Molecular Phenotypes and Sheds Light on The Pathways They Control. *BMC Genomics*. *14*(643): 1-19.
- Du, J. and Xu, R. 2012. ROR α , A Potential Tumor Suppressor and Therapeutic Target of Breast Cancer. *Int J Mol Sci*. *13*(12): 15755-15766.
- Dweep, H., Georgiou, G.D., Gretz, N., *et al.* 2013. CNVs-MicroRNAs Interactions Demonstrate Unique Characteristics in the Human Genome. An Interspecies *In Silico* Analysis. *PLOS ONE*. *8*(2): 1-7.
- Egejuru, R.O., Nnadi, I.C., and Duru, O.N. 2017. Fibroadenoma in Blacks. *Health*. *9*: 1475-1481.
- Engström, M.J., Opdahl, S., Hagen, A.I., *et al.* 2013. Molecular Subtype, Histopathological Grade and Survival in A Historic Cohort of Breast Cancer Patient. *Breast Cancer Res Treat*. *140*: 463-473.
- Eroles, P., Bosch, A., Pérez-Fidalgo, A., *et al.* 2012. Molecular Biology in Breast Cancer: Intrinsic Subtypes and Signaling Pathway. *Cancer Treatment Reviews*. *38*:698-707.
- Esteller, M. 2011. Non-Coding RNAs in Human Disease. *Nature Reviews Genetics*. *12*: 861-874.
- Fadjari, H. 2012. Pendekatan Diagnosis Benjolan di Payudara. *CDK-192*. *39*(4): 308-310.
- Fakhrehani, E. and Toi, M. 2014. Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials. *Jpn J Clin Oncol*. *44*(3): 197-207.
- Faraoni, I., Antonetti, F.R., Cardone, J., *et al.* 2009. MiR-155 Gene: A Typical Multifunctional MicroRNA. *Biochimica et Biophysica Acta*. *1792*: 497-505.

- Fathers, K.E., Bell, E.S., Rajadurai, C.V., *et al.* 2012. Crk Adaptor Proteins Act as Key Signaling Integrators for Breast Tumorigenesis. *Breast Cancer Research*. 14: 1-15.
- Fatica, A. and Bozzoni, I. 2014. Long Non-Coding RNAs: New Players in Cell Differentiation and Development. *Nature Reviews Genetics*. 15: 7-21.
- Felekakis, K., Voskarides, K., Dweep, H., *et al.* 2011. Increased Number of MicroRNA Target Sites in Genes Encoded in CNV Regions. Evidence for an Evolutionary Genomic Interaction. *Mol. Biol., Evol.* 28(9): 2421-2424.
- Felmeden, D.C., Blann, A.D., and Lip, G.Y.H. 2003. Angiogenesis: Basic Pathophysiology and Implications for Disease. *Eur Heart J*. 24: 586-600.
- Ferlay, J., Soerjomataram, I., Dikshit, R., *et al.* 2015. Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012. *Int. J. Cancer*. 136: E359-E386.
- Ferrara, N. and Kerbel, R.S. 2005. Angiogenesis as A Therapeutic Target. *Nature*. 438: 967-974.
- Frith, M. C., Bailey, T. L., Kasukawa, T., *et al.* 2006. Discrimination of Non-Protein-Coding Transcript from Protein-Coding RNA. *RNA Biology*. 3(1): 40-48.
- Folkman, J. 2007. Is Angiogenesis an Organizing Principle in Biology and Medicine?. *Journal of Pediatric Surgery*. 42: 1-11.
- Fouad, Y.A. and Aanei, C. 2017. Revisiting The Hallmarks of Cancer. *Am. J. Cancer. Res*. 7(5): 1016-1036.
- Fox, S.B., Generali, D.G., and Harris, A.L. 2007. Breast Tumour Angiogenesis. *Breast Cancer Research*. 9(126): 1-11.
- Franco, N., Arnould, L., Mege, F., *et al.* 2003. Comparative Analysis of Molecular Alterations in Fibroadenomas Associated or Not With Breast Cancer. *Arch Surg*. 138: 291-295.
- Fu, S. W., Chen, L., and Man, Y-G. 2011. miRNA Biomarkers in Breast Cancer Detection and Management. *Journal of Cancer*. 2: 116-123.
- Gallach, S., Calabuig-Farinas, S., Jantus-Lewintre, *et al.* 2014. MicroRNAs: Promising New Antiangiogenic Targets in Cancer. *Biomed Research International*. 1-14.
- Gao, Y., Feng, B., Han, S., *et al.* 2016. The Roles of MicroRNA-141 in Human Cancers: From Diagnosis to Treatment. *Cell Physiol Biochem*. 38: 427-448.
- Garzon, R., Fabbri, M., Cimmino, A., *et al.* 2006. MicroRNA Expression and Function in Cancer. *TRENDS in Molecular Medicine*. 12(12): 580-587.
- Geiss, G.K., Bumgarner, R.E., Birditt, B., Dahl, T., *et al.* 2008. Direct Multiplexed Measurement of Gene Expression with Color-Coded Probe Pairs. *Nature Biotechnology*. 26(3): 317-325.
- George, G.P. and Mittal, R.D. 2010. MicroRNAs: Potential Biomarkers in Cancer. *Indian Journal of Clinical Biochemistry*. 25(1): 4-14.
- Gloss, B.S. and Dinger, M.E. 2015. The Specificity of Long Noncoding RNA Expressions. *Biochims. Biophys. Acta*. 1-20.
- Gutschner, T. and Diederichs, S. 2012. The Hallmarks of Cancer. *RNA Biology*. 9(6): 703-719.
- Greer, S.N., Metcalf, J.L., Wang, Y., *et al.* 2012. The Updated Biology of Hypoxia-

- Inducible Factor. *The EMBO Journal*. 31: 2448-2460.
- Grochot-Przeczek, A., Kotlinowski, J., Kozakowska, M., *et al.* 2014. Heme Oxygenase-1 is Required for Angiogenic Function of Bone Marrow-Derived Progenitor Cells: Role in Therapeutic Revascularization. *Antioxid Redox Signal*. 20(11): 1677-1692.
- Gulyaeva, L.F. and Kushlinskiy, N.E. 2016. Regulatory Mechanisms of MicroRNA Expression. *J Transl Med*. 43(143): 1-10.
- Hall, A.P. 2005. The Role of Angiogenesis in Cancer. *Comp. Clin. Path.* 13: 95-99.
- Hanahan, D. and Weinberg, R.A. 2011. Hallmarks of Cancer: The Next Generation. *Cell*. 144(5): 646-674.
- Hayes, E. 2012. Acquired Tamoxifen Resistance and Promotion of Angiogenic Responses in Breast Cancer. [Disertation]. Cardiff University. Wales.
- Hejmadi, M. 2010. Introduction to Cancer Biology. 2nd Edition. *Bookboon*. 1-48.
- Hemmatzadeh, M., Mohammadi, H., Jadidi-Niaragh, F., *et al.* 2016. The Role of Oncomirs in The Pathogenesis and Treatment of Breast Cancer. *Biomedicine and Pharmacotherapy*. 78: 129-139.
- Hoff, P.M. and Machado, K.K. 2012. Role of Angiogenesis in The Pathogenesis of Cancer. *Cancer Treatment Reviews*. 38: 825-833.
- How, C. 2003. Characterization of Altered MicroRNA Expression in Cervical Cancer. [Disertation]. University of Toronto. Kanada.
- Huo, D., Clayton, W.M., Yoshimatsu, T.F., *et al.* 2016. Identification of a Circulating MicroRNA Signature to Distinguish Recurrence in Breast Cancer Patients. *Oncotarget*. 34(7): 55231-55248.
- Iorio, M.V. and Croce, C.M. 2011. MicroRNA Dysregulation in Cancer: Diagnostics, Monitoring and Therapeutics. A Comprehensive Review. *EMBO Mol Med*. 4: 143-159.
- Jain, R. K. 2001. Normalizing Tumor Vasculature with Anti-Angiogenic Therapy: A New Paradigm for Combination Therapy. *Nature Medicine*. 7(9): 987-989.
- Kementerian Kesehatan RI. 2015. Stop Kanker: Situasi Penyakit Kanker. *Infodatin*. 1-8.
- Kim, Y.S., Park, S.J., Lee, Y.S., *et al.* 2016. miRNAs Involved in LY6K and Estrogen Receptor α Contribute to Tamoxifen-Susceptibility in Breast Cancer. *Oncotarget*. 7(27): 42261-42273.
- Klevos, G.A., Ezuddin, N.S., Vinyard, A., *et al.* 2017. A Breast Cancer Review: Through the Eyes of The Doctor, Nurse, and Patient. *Journal of Radiology Nursing*. 36: 158-165.
- Kodaz, H., Kostek, O., Hacıoglu, M.B., *et al.* 2017. Frequency of RAS Mutations (KRAS, NRAS, HRAS) in Human Solid Cancer. *EJMO*. 1(1): 1-7.
- Kong, D-H., Kim, M.R., Jang, J.H., *et al.* 2017. A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy. *Int J Mol Sci*. 18: 1-25.
- Kresno, S.B. 2011. Micro-RNA dan Implikasinya pada Kanker. *Indonesian Journal of Cancer*. 5(3): 119-127.
- Krishnan, P., Ghosh, S., Wang, B., *et al.* 2015. Next Generation Sequencing Profiling Identifies miR-574-3p and miR-660-5p as Potential Novel Prognostic Markers for Breast Cancer. *BMC*. 16(735): 1-17.
- Krock, B.L., Skuli, N., and Simon, M.C. 2011. Hypoxia-Induced Angiogenesis:

- Good and Evil. *Genes & Cancer*. 2(12): 1117-1133.
- Krol, J., Loedige, I., and Filipowicz, W. 2010. The Widespread Regulation of MicroRNA Biogenesis, Function and Decay. *Nature*. 11: 597-610.
- Kujiper, A., Mommers, E.C.M., van der Wall, E., *et al.* 2011. Histopathology of Fibroadenoma of the Breast. *Am. J. Clin. Pathol.* 115: 736-742.
- Kulkani, M.M. 2011. Digital Multiplexed Gene Expression Analysis using The NanoString nCounter System. *Curr Protoc Mol Biol*. 94: 1-17
- Kumar, V., Abbas, A.K., Fausto, N., *et al.* 2015. *Robbins and Cotran Pathologic Basis of Disease*. 8th Edition. Philadelphia: Saunders Elsevier. pp. 1043-1072.
- Kung, J.T.Y., Colognori, D., and Lee, J.T. 2013. Long Noncoding RNAs: Past, Present, and Future. *Genetics*. 193: 651-669.
- Kurozumi, S., Yamaguchi, Y., Kurosumi, M., *et al.* 2017. Recent Trends in MicroRNA Research into Breast Cancer with Particular Focus on The Association Between MicroRNAs and Intrinsic Subtypes. *J Hum Genet*. 62(1): 15-24.
- Laar, R.V., Lincoln, M., and Laar, B.V. 2018. Development and Validation of Plasma-based Melanoma Biomarker Suitable for Clinical Use. *British Journal of Cancer*. 118: 857-866.
- Landskroner-Eiger, S., Moneke, I., and Sessa, W.C. 2013. miRNAs as Modulator of Angiogenesis. *Cold Spring Harb Perfect Med*. 1-14.
- Lee, M. and Soltanian, H.T. 2015. Breast Fibroadenoma in Adolescents: Current Perspective. *Adolescent Health, Medicine, and Therapeutics*. 6: 159-169.
- Lee, T-L, Xiao, A., and Rennert, O.M. 2012. Identification of Novel Long Noncoding RNA Transcripts in Male Germ Cells. *Methods. Mol. Biol.* 825: 105-114.
- Lenzi, P., Bocci, G., and Natale, G. 2016. John Hunter and The Origin of The Term "Angiogenesis". *Angiogenesis*. 19: 225-256.
- Li, J., Jia, S., Zhang, W., *et al.* 2013. Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target Therapy. *ISRN Oncol*. 1-8.
- Libson, S. and Lippman, M. 2014. A Review of Clinical Aspect of Breast Cancer. *International Review of Psychiatry*. 26(1): 4-15.
- Liu, C-Y., Wu, C-Y., Petrossian, K., *et al.* 2017. Treatment for The Endocrine Resistance Breast Cancer: Current Options and Future Perspective. *Journal of Steroid Biochemistry and Molecular Biology*. 1-43.
- Loizi, V., Vecchio, V.D., Gargano, G., *et al.* 2017. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer. *Int. J. Mol. Sci.* 18: 1-11.
- Loke, B.N., Nasir, N.D.M., Thike, A.A., *et al.* 2017. Genetics and Genomics of Breast Fibroadenomas. *J. Clin. Pathol.* 71: 381-387.
- Lopéz-Camarillo, C., Marchat, L.A., Aréchaga-Ocampo, E., *et al.* 2013. Functional Roles of MicroRNAs in Cancer: MicroRNomes and OncomiRs Connection. *Intech*. 71-90.
- Lou, W., Liu, J., Gao, Y., *et al.* 2017. MicroRNAs in Cancer Metastasis and

- Angiogenesis. *Oncotarget*. 8(70): 115787-115802.
- Lu, J. and Clark, A.G. 2012. Impact of MicroRNA Regulation of Variation in Human Gene Expression. *Genome Research*. 22:1243-1254.
- Luengo-Gil, G., Gonzalez-Billalabeitia, E., Perez-Henarejos, S.A., *et al.* Angiogenic role of miR-20a in Breast Cancer. *PlosOne*. 1-17.
- Lv, X., Li, J., Zhang, C., *et al.* 2017. The Role of Hypoxia-Inducible Factors in Tumor Angiogenesis and Cell Metabolism. *Genes and Diseases*. 4: 19-24.
- Ma, R., Gong, J., and Jiang, X. 2017. Novel Application of Next-Generation Sequencing in Breast Cancer Research. *Genes and Diseases*. 1-5.
- Macfarlane, L.A. and Murphy, P.R. 2010. MicroRNA: Biogenesis, Function and Role in Cancer. *Curr Genomics*. 11(7): 537-561.
- Majmundar, A.J., Wong, W.J., and Simon, M.C. 2010. Hypoxia-Inducible Factors and The Response to Hypoxic Stress. *Molecular Cell*. 40: 294-309.
- McGuire, A., Brown, J.A., and Kerin, M.J. 2015. Metastatic Breast Cancer: The Potential of miRNA for Diagnosis and Treatment Monitoring. *Cancer Metastasis Rev*. 34(1): 145-155.
- Makki, J. 2015. Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance. *Clinical Medical Insight: Pathology*. 8: 23-31.
- Malvia, S., Bagadi, S.A., Dubey, U.S., *et al.* 2017. Epidemiology of Breast Cancer in Indian Women. *Asia Pac J Clin Oncol*. 13(4): 289-295.
- Maria, I.L., Sainal, A.S., and Nyorong, M. 2017. Risiko Gaya Hidup Terhadap Kejadian Kanker Payudara pada Wanita. *Jurnal MKMI*. 13(2): 157-166.
- Mattick, J.S. and Makunin, I.V. 2006. Non-Coding RNA. *Human Molecular Genetics*. 15(1): R17-R29.
- Mattie, M.D., Benz, C.C., Bowers, J., *et al.* 2006. Optimized High-Throughput MicroRNA Expression Profiling Provides Novel Biomarker Assessment of Clinical Prostate and Breast Cancer Biopsies. *Mol Cancer*. 5(24): 1-14.
- Mavaddat, N., Antoniou, A.C., Easton, D.F., *et al.* 2010. Genetic Susceptibility to Breast Cancer. *Molecular Oncology*. 4: 174-191.
- Mayer, I.A. and Arteaga, C.L. 2016. The PI3K/AKT Pathway as A Target for Cancer Treatment. *Annu. Rev. Med*. 67: 15.1-15.18.
- Maeshima, Y. 2007. Angiogenesis and Cancer. *Apoptosis, Cell Signaling, and Human Diseases: Molecular Mechanism*. 1: 35-59.e
- Mauri, D., Pavlidis, N., Polyzos, N.P., *et al.* 2006. Survival with Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-Analysis. *J. Natl. Cancer Inst*. 98:1285-1291.
- Mehrgou, A. and Akouchekian, M. 2017. Therapeutic Impacts of MicroRNAs in Breast Cancer by Their Roles in Regulating Processes Involved in This Disease. *J Res Med Sci*. 1-12.
- Miller, K., Wang, M., Gralow, J., *et al.* 2007. Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer. *N. Engl J Med*. 357: 2666-2676.
- Moore, K.J., Rayner, K.J., Suarez, Y., *et al.* 2011. The Role of MicroRNAs in Cholesterol Efflux and Hepatic Lipid Metabolism. *Annu. Rev. Nutr*. 31: 49-63.
- Morris, K.V. and Mattick, J.S. 2014. The Rise of Regulatory RNA. *Nature Reviews*

Genetics. 1-15.

- Murphy, C.G. and Dickler, M.N. 2016. Endocrine Resistance in Hormone-Responsive Breast Cancer: Mechanisms and Therapeutic Strategies. *Endocrine-Related Cancer*. 23: R337-R352.
- Nagano, T. and Fraser, P. 2011. No-Nonsense Functions for Long Noncoding RNAs. *Cell*. 145: 178-181.
- Nahta, R. 2012. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. *ISRN Oncol*. 1-16.
- NanoString Technologies, 2013. nCounter[®] miRNA Expression Assay User Manual. MAN-C0009-05. 3-14.
- Onitilo, A.A., Engel, J.M., Greenlee, R.T., *et al.* 2009. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. *Clinical Medicine and Research*. 7(1/2): 4-13.
- Palazzo, A.F. and Lee, E.S. 2015. Non-Coding RNA: What is Functional and What is Junk?. *Frontiers in Genetics*. 6(2): 1-11.
- Papadopoulos, G.L., Alexiou, P., Maragkakis, M., *et al.* 2009. DIANA-miRrPath: Integrating Human and Mouse MicroRNA in Pathways. *Bioinformatics*. 25(15): 1991-1993.
- Paplomata, E. And O'Regan, R. 2014. The PI3K/AKT/mTOR Pathway in Breast Cancer: Targets, Trials, and Biomarkers. *Ther Adv Med Oncol*. 6(4): 154-166.
- Papetti, M. and Herman, I.M. 2002. Mechanisms of Normal and Tumor-derived Angiogenesis. *Am. J. Physiol. Cell. Physiol*. 282: C947-C970.
- Park, C.J., Kim, E-K., Woo, H.Y., *et al.* 2015. Breast Cancer Arising Adjacent to an Involuting Fibroadenoma: Serial Changes in Radiologic Features. *J. Breast Cancer*. 18(3): 291-295.
- Perou, C.,M., Sørli, T., Eisen, M.B., *et al.* 2000. Molecular Portraits of Human Breast Cancer. *Nature*. 406(6797): 747-752.
- Poon, R.T-P., Fan, S-T., and Wong, J. 2001. Clinical Implication of Circulating Angiogenic Factors in Cancer Patients. *Journal of Clinical Oncology*. 19(4): 1207-1225.
- Potente, M., Gerhardt, H., and Carmeliet, P. 2011. Basic and Therapeutic Aspect of Angiogenesis. *Cell*. 146: 873-887.
- Presner, J. R. and Chinnaiyan, A. M. 2011. The Emergence of LncRNAs in Cancer Biology. *Cancer Discovery*. 391-407.
- Putri, N.P.Y. dan Hudyono, J. 2014. Diagnosis dan Penatalaksanaan Fibroadenoma Payudara. *J. Kedokt. Meditek*. 20(53): 37-45.
- Rasheed, Z. 2017. Bioinformatics Approach: A Powerful Tool for MicroRNA Research. *Int J Health Sci (Qassim)*. 11(3): 1-3.
- Rodriguez, S. and Huynh-Do, U. 2012. The Role of PTEN in Tumor Angiogenesis. *Journal of Oncology*. 1-11.
- Rohan, T., Ye, K., Wang, Y., *et al.* 2018. MicroRNA Expression in Benign Breast Tissue and Risk of Subsequent Invasive Breast Cancer. *pLos One*. 1-13.
- Rivenbark, A.G., O'Connor, S.M., and Coleman, W.B. 2013. Molecular and Cellular Heterogeneity in Breast Cancer Challenges for Personalized Medicine. *The American Journal of Pathology*. 183(4): 1113-1124.
- Saito, S., Lin, Y-C., Tsai, M-H., *et al.* 2015. Emerging Roles of Hypoxia-Inducible

- Factors and Reactive Oxygen Species in Cancer and Pluripotent Stem Cells. *J. Med. Sci.* 31: 279-286.
- Schubert, R. 2012. Invasive Ductal Breast Cancer (IDC). *Breast Cancer Care.* 1-12.
- Shen, Y., Ye, Y.F., Ruan, L.W., *et al.* 2017. Inhibition of miR-660-5p Expression Suppresses Tumor Development and Metastasis in Human Breast Cancer. *Genetics and Molecular Research.* 1(16): 1-11.
- Shen, S. 2016. Developing an Alternative Way to Analyze NanoString Data. *Theses and Dissertation-Statistic.* 1-75.
- Shen, G., Li, X., Jia, Y-F., *et al.* 2013. Hypoxia-Regulated MicroRNAs in Human Cancer. *Acta Pharmacol Sin.* 34(3): 336-341.
- Shi, Y., Luo, X., Li, P., *et al.* 2015. miR-7-5p Suppresses Cell Proliferation and Induces Apoptosis of Breast Cancer Cells Mainly by Targeting REGγ. *Cancer Letters.* 358(1): 27-36.
- Slack, F.J. and Weidhass, J.B. 2008. MicroRNA in Cancer Prognosis. *N Engl J Med.* 359(25): 2720-2722.
- Sørli, T., Tibshirani, R., Parker, J., *et al.* 2003. Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets. *PNAS.* 100(14): 8418-8423.
- Stacker, S.A. and Achen, M.G. 2013. The VEGF Signaling Pathway in Cancer: The Road Ahead. *Chin J Cancer.* 32(6): 297-302.
- Stephenson, J.A., Goddard, J.C., Al-Taani, O., *et al.* 2013. Tumor Angiogenesis: A Growth Area- From John Hunter to Judah Folkman and Beyond. *Journal of Cancer Research.* 1-6.
- Sun, W. 2012. Angiogenesis in Metastatic Colorectal Cancer and The Benefit of Targeted Therapy. *Journal of Hematology and Oncology.* 63(5): 1-9.
- Suzuki, H., Maruyama, R., Yamamoto, E., *et al.* 2012. DNA Methylation and MicroRNA Dysregulation in Cancer. *Molecular Ontology.* 567-578.
- Swarbrick, A., Woods, S.L., Shaw, A., *et al.* 2010. miR-380-5p Represses p53 to Control Cellular Survival and is Associated with Poor Outcome in MYCN-Amplified Neuroblastoma. *Nat. Med.* 16: 1134-1140.
- Tahiri, A., Leivonen, S., Luders, T., *et al.* 2014. Deregulation of Cancer-Related miRNAs is A Common Event in Both Benign and Malignant Human Breast Tumors. *Carcinogenesis.* 35(1): 76-85.
- Taslim, C., Weng, D.Y., Brasky, T.M., *et al.* 2016. Discovery and Replication of MicroRNAs for Breast Cancer Risk using Genome-Wide Profiling. *Oncotarget.* 7(52): 86457-86468.
- Tassi, E. and Wellstein, A. 2006. Tumor Angiogenesis: Initiation and Targeting- Therapeutic Targeting of an FGF-Binding Protein, an Angiogenic Switch Molecule, and Indicator of Early Stages of Gastrointestinal Adenocarcinomas. *Cancer Res Treat.* 38(4): 189-197.
- The ENCODE Project Consortium, 2012. An Integrated Encyclopedia of DNA Element in The Human Genome. *Nature* 489: 57-74.
- Torre, L.A., Siegel, R.L., Ward, E.M., *et al.* 2015. Global Cancer Incidence and Mortality Rates and Trends-An Update. *Cancer Epidemiol Biomarkers Prev.* 25(1): 16-27.

- Ucuzian, A.A., Gassman, A.A., East, A.T., *et al.* 2010. Molecular Mediators of Angiogenesis. *J. Burn. Care. Res.* 31(1): 1-28.
- van Schooneveld, E., Wildiers, H., Vergote, I., *et al.* 2015. Dysregulation of microRNAs in Breast Cancer and Their Potential Role as Prognostic and Predictive Biomarkers in Patients Management. *Breast Cancer Res.* 17(21): 1-15.
- Veldman-Jones, M.H., Brant, R., Rooney, C., *et al.* 2015. Evaluating Robustness and Sensitivity of The NanoString Technologies nCounter Platform to Enable Multiplexed Gene Expression Analysis of Clinical Sample. *Cancer Res.* 75(13): 2587-2593.
- Vennin, C., Dahmani, F., Spruyt, N., *et al.* 2013. Role of Long Non-Coding RNA in Cells: Example of The *H19/IGF2* Locus. *Advances in Bioscience and Biotechnology.* 4: 34-44.
- Vlachos, I.S., Zagganas, K., Paraskevopoulou, M.D., *et al.* 2015. DIANA-miRPath v3.0: Deciphering MicroRNA Function with Experimental Support. *Nucleic Acids Research.* 43: W460-W466.
- Visone, R. and Croce, C.M. 2009. miRNAs and Cancer. *Am J Pathol.* 174(4): 1131-1138.
- Volinia, S., Galasso, M., Sanam M.E., *et al.* 2012. Breast Cancer Signatures for Invasiveness and Prognosis Defined by Deep Sequencing of MicroRNA. *PNAS.* 109(8): 3024-3029.
- Vonilia, S., Calin, G.A., Liu, C.G., *et al.* 2006. A MicroRNA Expression Signature of Human Solid Tumor Defines Cancer Gene Targets. *Proc Natl Acad Sci USA.* 103: 2257-2261.
- Voorhoeve, P.M. 2010. MicroRNAs: Oncogenes Tumor Suppressors or Master Regulators of Cancer Heterogeneity?. *Biochimica et Biophysica Acta.* 72-86.
- Wang, K.K., Yang, Z., Zhu, T., *et al.* 2018. An Update on Diagnostic and Prognostic Biomarkers for Traumatic Brain Injury. *Expert Rev Mol Diagn.* 18(2): 165-180.
- Wang, X., Jiang, D., Xu, C., *et al.* 2017. Differential Expression Profile Analysis of miRNAs with HER2 Overexpression and Intervention in Breast Cancer Cells. *Int J Clin EXP Pathol.* 5(10): 5039-5062.
- Wang, S., Li, H., Wang, J., *et al.* 2014. Prognostic and Biological Significance of Micro-RNA-127 Expression in Human Breast Cancer. *Dis Markers.* 1-12.
- Wang, K.C. and Chang, H.Y. 2011. Molecular Mechanisms of Long Noncoding RNAs. *Mol. Cell.* 43(6): 904-914.
- Weigelt, B. And Reis-Filho, J.S. 2009. Histological and Molecular Types of Breast Cancer: Is There a Unifying Taxonomy?. *Nat. Rev. Clin. Oncol.* 6: 718-730.
- Widodo, I., Dwianingsih, E.K., Anwar, S.L., *et al.* 2017. Prognostic Value of eMolecular Subtype. *Asian Pasific Journal of Cancer Prevention.* 18: 1250-1256.
- Wigerup, C., Pahlman, S., and Bexell, D. 2016. Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer. *J. Pharmacology and Therapeutic.* 152-169.
- Wu, Y-T., Chen, S-T., Chen, C-J., *et al.* 2014. Breast Cancer Arising Within Fibroadenoma: Collective Analysis of Case Reports in The Literature and Hints on Treatment Policy. *World Journal of Surgical Oncology.* 12: 335-

343.

- Wu, E., Thivierge, C., Flamand, M., *et al.* 2010. Pervasive and Cooperative Deadenylation of 3'UTRs by Embryonic MicroRNA Families. *Molecular Cell*. 40(3): 558-570.
- Yan, M., Li, X., Tong, D., *et al.* 2016. miR-136 Suppresses Tumot Invasion and Metastasis by Targeting RASAL2 in Triple-Negative Breast Cancer. *Oncology Report*. 36(1): 65-71.
- Yan, H., Choi, A-J., Lee, B.H., *et al.* 2011. Identification and Functional Analysis of Epigenetically Silenced MicroRNAs in Colorectal Cancer Cells. *PloS One*. 6(6): 1-11.
- Yang, Y., Jiang, Z., Ma, N., *et al.* 2018. Micro-RNA-223 Targeting STIM1 Inhibits the Biological Behavior of Breast Cancer. *Cellular Pathology and Biochemistry*. 45(2): 856-866.
- Youliden, D.R., Cramb, S.M., Yip, C.H., *et al.* 2014. Incidence and Mortality of Female Breast Cancer in The Asia-Pacific Region. *Cancer Biology and Medicine*. 101-115.
- Zakaria, F. and Ahmed, S. 2016. Histological Variation in Fibroadenoma of Breast. *International Journal of Biomedical Research*. 7(11): 760-764.
- Zhang, Q. 2017. Long Non-Coding RNAs as Regulators of Angiogenesis: A Mini-Review. *Cell. Mol. Med. Res*. 1(1): 7-10.
- Zhang, X., Jiang, P., Shuai, L., *et al.* 2016. miR-589-5p Inhibits MAP3K8 and Suppresses CD90⁺ Cancer Stem Cells in Hepatocellular Carcinoma. *Journal of Experimental and Clinical Cancer Research*. 36(176): 1-12.
- Zhang, M.H., Man, H.T., Zhao, X.D., *et al.* 2013. Estrogen Receptor-Positive Breast Cancer Molecular Signatures and Therapeutic Potentials. *Biomedical Report*. 2: 41-52.
- Zhao, M. and Ramaswamy, B. 2014. Mechanisms and Therapeutic Advances in The Management of Endocrine Resistant Breast Cancer. *World J Clin Oncol*. 5(3): 248-262.